ストックスクリーナーアプリを入手
55.75
0.52%
-0.29
アフターアワーズ：
55.75
Tg Therapeutics Inc (TGTX) 最新ニュース
TGTX Maintains Buy Rating -- Price Target Raised to $86.00 by B. Riley Securities - GuruFocus
META_TITLE_QUOTE - Yahoo Finance
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
B. Riley Raises Price Target on TG Therapeutics to $86 From $55, Keeps Buy Rating - marketscreener.com
TG Therapeutics Inc (TGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TG THERAPEUTICS INC : B. RILEY RAISES TARGET PRICE TO $86 FROM $55 - Bitget
TG Therapeutics, Inc. Revenue Breakdown – FWB:NKB2 - TradingView
TradingKey - TradingKey
TG Therapeutics Inc (TGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TG Therapeutics Inc (TGTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TG Therapeutics, Inc. Revenue Breakdown – LS:A1JXW7 - TradingView
TGTX|TG Therapeutics Inc|Price:56.040|Chg%:+0.540 - TradingKey
TGTX|TG Therapeutics Inc|Price:56.650| - TradingKey
TG Therapeutics, Inc. (TGTX) stock price, news, quote and history - Yahoo Finance UK
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TG Therapeutics Inc (TGTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TGTX: TG Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
TG Therapeutics Inc (TGTX) Fundamental & Financial Data - Stocktwits
TG Therapeutics Holds Steady Near $54 Amid ConsolidationValue Area Low - dars.gov.et
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm - Morningstar
(TGTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Triangle's highest-paid public company CEO earned $25M in 2025. Here's how others stacked up. - The Business Journals
TG Therapeutics, Inc. (TGTX): Investor Outlook on a Biotech Powerhouse with 6.39% Upside Potential - DirectorsTalk Interviews
TG THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $75 FROM $50 - Bitget
TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch - Stocktwits
ETFs Investing in TG Therapeutics, Inc. Stocks - TradingView
Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm - GlobeNewswire Inc.
Did BRIUMVI’s Phase 2 Schizophrenia Trial Just Shift TG Therapeutics' (TGTX) Investment Narrative? - simplywall.st
TG THERAPEUTICS INC : JP MORGAN RAISES TARGET PRICE TO $65 FROM $46 - webull.com
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX) - The Globe and Mail
TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Jefferies Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $83 - Moomoo
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $77 - Moomoo
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations - Yahoo Finance
TGTX Maintained by HC Wainwright & Co. -- Price Target Raised to $77 - GuruFocus
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Healthcare Standout with Robust Revenue Growth - DirectorsTalk Interviews
Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch? - Sahm
TG Therapeutics Initiates Phase 2 Trial of Briumvi, Expanding Pipeline PotentialGuidance Upgrade Report - DonanımHaber
TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss - Stocktwits
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Insider Monkey
TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News - Yahoo Finance
2 Fast-Growing Pharmaceutical Stocks to Buy Now - The Motley Fool
Can TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI’s Role Beyond Multiple Sclerosis? - Yahoo Finance
Is TG Therapeutics (TGTX) Fully Valued Following Its Schizophrenia Trial Update? - Yahoo Finance
Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX) - The Globe and Mail
5 Best Performing American Stocks in June 2026 - Insider Monkey
Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says - Moomoo
TGTX Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
TG Therapeutics stock hits 52-week high at 57.4 USD By Investing.com - Investing.com Nigeria
TG Therapeutics stock hits 52-week high at 57.4 USD - Investing.com
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia - The Globe and Mail
TG Therapeutics, Inc. Stock 12‑Month Price Target Raised to $52.14, Implies 6% Downside - TradingView
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):